| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we have analyzed the role of Ras-Raf-ERK/MAPK and its endogenous inhibitor, Spred-2 in various animal models, using Spred-2 knock-out (KO) mice. We have demonstrated that Spred-2 plays a central role in the regulation of inflammation in various types of inflammation. Our results suggest that Spred-2 can be a new target for controlling inflammation. We also demonstrated that Spred-2 expressed in clinical cancer tissue may be involved carcinogenesis and cancer progression. Furthermore, our results indicate that Spred-2 may be essential regulator of cancer metastasis by modulating epithelial mesenchymal transition (EMT).
|
